LAW REVIEW PUBLICATIONS
A. Foulkes, Genetic Villains, S.C. L. Rev, forthcoming
J. Roberts & A. Foulkes, Genetic Duties, 62 Wm. & Mary L. Rev. 143 (2020).
A. Foulkes, Liberty’s Limits & Editing Humanity, 98 N.C. L. Rev 1549 (2019).
A. Foulkes, J. Roberts et al., Clinical Genetics Laboratories & Medical Malpractice, 29 Annals Health L. & Life Sci. 153 (2020).
A. Foulkes et al., Legal and Ethical Implications of CRISPR Applications in Psychiatry, 97 N.C. L. Rev. 1359 (2019).
A. Foulkes, Comment, The Evolutionary Tradition in Law and Metaphor’s Double-Edged Sword, 56 Hous. L. Rev. 103 (2018).
M. Sidhu, P. Thompson, B. Wandschneider, A. Foulkes et al., The Impact of Brain‐Derived Neurotrophic Factor Val66Met Polymorphism on Cognition and Functional Brain Networks in Patients with Intractable Partial Epilepsy, 25 C.N.S. Neurosci. & Ther. 223 (2019).
C. Brannan, A. Foulkes & G. Lazaro-Muñoz, Preventing Undue Discrimination Based on Psychiatric Risk Biomarkers, 180 Am. J. Med. Genet. 159 (2019).
J. Murrough, K. Burdick, C. Levitch, A. Perez, J. Brallier, L. Chang, A. Foulkes et al., Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial, 40 Neuropsychopharm. 1084 (2015).
A. Foulkes et al., Clinical Moderators of Antidepressant Response to Ketamine: A Bayesian Analysis, 75 Biol. Psych. 126S (2015).
C. Haile, J. Murrough, D. Iosifescu, L. Chang, R. Al Jurdi, A. Foulkes et al., Plasma Brain Derived Neurotrophic Factor (BDNF) and Response to Ketamine in Treatment-Resistant Depression, 17 Int. J. Neuropsychopharm. 331 (2014).
R. Price, D. Iosifescu, J. Murrough, L. Chang, R. Al Jurdi, S. Iqbal, L. Soleimani, D. Charney, A. Foulkes et al., Effects of Ketamine on Explicit and Implicit Suicidal Cognition: A Randomized Controlled Trial in Treatment‐Resistant Depression, 31 Depression & Anxiety 335 (2014).
J. Murrough, D. Iosifescu, L. Chang, R. Al Jurdi, C. Green, A. Perez, S. Iqbal, S. Pillemer, A. Foulkes et al., Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial, 170 Am. J. Psych. 1134 (2013).
J. Stretton, A. Foulkes et al., Does the BDNF Val66Met Polymorphism Influence Cognitive Function in Patients with mTLE?, 53 Epilepsia 39 (2012).